Navigation Links
PetlinQ Signs Agreement With SpeakLike for Accurate, Real-Time Translation Chat
Date:2/8/2008

Translation chat improves cross-language customer support and collaboration

NEW YORK, Feb. 8 /PRNewswire/ -- SpeakLike, Inc. announced today that PetlinQ(TM), a web-based application used to transport diagnostic images and reports from medical facilities to referring physicians, has signed on to use the new SpeakLike (TM) translation service.

SpeakLike is the first Internet chat translation service that seamlessly integrates automated and human translation, a technology that offers the accuracy of human interpretation, but at a far lower cost than existing interpretation services. The service makes it possible to type text in one's own language and have others see it in theirs, accurately and within seconds.

President & CEO of PetlinQ Harsha Hatti, sees SpeakLike as an invaluable tool for doctors, patients and the entire healthcare sector:

"With SpeakLike, users such as doctors and patients will be able to pull up the same patient images in different languages and collaboratively via chat online instantly -- and accurately. This is just one of the many ways that SpeakLike will make communicating in the world of healthcare easier and safer."

Although English is considered the language of healthcare, there are nuances in all languages that cannot be translated to English. Doctors and patients will feel much more comfortable speaking in their native languages because it means they can communicate what they truly mean.

SpeakLike will also help PetlinQ's staff provide better service and support to the doctors, radiologists, clinic staff and patients in the imaging centers and hospitals that use its software.

Harsha Hatti explains the significant value of this service, particularly to patients: "When patients have important questions, they communicate through our chat tool in English. For many of those patients, where English isn't their first language, they will now be able to tell our staff exactly what they want or ne
'/>"/>

SOURCE SpeakLike, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses
2. The onchocerciasis parasite showing signs of resistance
3. Xoft Signs Sales Development Agreement With Elekta
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG (Hamburg, Germany)
6. Cambrex Signs Agreement To Acquire ProSyntest AS
7. CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems
8. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
9. Nationwide Respiratory Signs Preferred Pulse Oximetry Agreement with Masimo
10. Claimsnet Signs Electronic Transaction Services Agreement With Employee Benefit Services of San Antonio
11. Flagship Global Health Chairman Resigns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...erville-based civil litigation and criminal defens...after jury awarded $3.2 million to plaintiff earli...e, Maryland ((Lexis Nexis) October 6, 2008 -- Atto...[Miller, Murtha & Psoras] have successfully re... Maryland welder who was awarded more than $3 mill...
(Date:10/5/2008)...ore healthy choices at schools, standard offerings...e giving students more calories than they need. ,...ide effort led by Temple University to curb obesit...ound vending machines beverages had added sugars, ...over 200 hundred calories. , The data will be pr...
(Date:10/5/2008)...cription drug samples distributed to children may ... Cambridge Health Alliance and Hasbro Children,s H...free drug sample use among children, appears in th...hors, who also serve as researchers at Harvard Med...f Brown University, found that children commonly r...
(Date:10/5/2008)...ized kids with painful ailments from broken bones ... drugs known as opiates. The medications block pai...ion, for instance, is one side effect that can cau...stay. , "No parent wants their child in the hosp... MD, MPH, medical director for quality management ...
Breaking Medicine News(10 mins):Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:School vending machines dole out excess calories, fat 2Health News:Free drug samples carry risks for children 2Health News:Major study of opiate use in children's hospitals provides simple steps to alleviate harm 2Health News:Major study of opiate use in children's hospitals provides simple steps to alleviate harm 3
...s that the risk of depression increases in women w...ls who are insulin-resistant may have higher serot...ression and even suicide. Researchers say Insu...with depression and that their results are consist...
...als that a tonsillectomy procedure using less ener... to reducing pain during recovery. // During a to...cial scalpel heats tissue as it goes along to cont...e microdissection needle technique uses less energ...
...s a vaccine made from the common cold virus may in...s.//Researchers from the Centers for Disease Contr...tically altered cold virus that is similar to part...ronavirus, called SARS-CoV, was discovered earlier...
...ws taking vitamin D and consuming a diet high in f...t can lead to colon cancer.// Researchers from 13...n 3,100 patients between ages 50 and 75. Results o...e than four grams of cereal fiber per day and more...
Other Medicine News:Health News:Preventing Colorectal Cancer 2
(Date:10/6/2008)...ntific Conference -, ORLANDO, Fla., Oct. 6 /PRNew...bia) today announced presentation of data from a p...at cyclic guanosine,monophosphate (cGMP) plays in ...rate that cGMP inhibits intestinal pain in a precl...itizes colonic afferent nerves in a,similar model ...
(Date:10/6/2008)...py is More Likely to Induce Steroid-Free Remissi... Immunomodulator, Azathioprine, OR... for the first time,from the Phase 3b Study of Pat...rs and Biologic Therapy (SONIC) may provide new in...moderate to severe Crohn,s disease.,According to f...
(Date:10/6/2008)...Naltrexone SR Associated with Bette.... 6 /- Orexigen Therapeutic...any focused on the treatment of,obesity and other ...esented,data showing the investigational drug, Con...lly achieved key objectives (lowered naltrexone,Cm...
(Date:10/5/2008)...f Medicine reaffirm,well-established efficacy and ...R), RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /PRNe...tential Long-term Impacts on Function with,Tiotrop...tiotropium bromide,inhalation powder), sustained i...measured by FEV(1) (p<0.001) versus placebo in Chr...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 1Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 2Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 3Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 4Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 5Regular exercise reduces risk of blood clots 6712 1Evolutionary comparison finds new human genes 1289 1Evolutionary comparison finds new human genes 1289 2Evolutionary comparison finds new human genes 1289 3New book presents methods to poke and prod individual molecules 1284 1New book presents methods to poke and prod individual molecules 1284 2
... -- Novagali Pharma, an,emerging ophthalmic pharma...ounces today positive results from the Phase III,c...from Vernal,Keratoconjunctivitis (VKC). In this or...signs of disease improved in patients,receiving Ve...(R),was excellent. , VKC is a severe form of chron...
...f the International,Society on Thrombosis and Haem...07 /PRNewswire/ --,Portola Pharmaceuticals, Inc. t...ts from EXPERT, a Phase II study of its oral Facto...enous,thromboembolism (VTE) following total knee r...Portola will advance PRT054021,into further clinic...
Other Medicine Technology:Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2Portola Pharmaceuticals Announces Positive Phase II Results for,PRT054021 for Prevention of Venous Thromboembolism Following Total,Knee Replacement Surgery 2Portola Pharmaceuticals Announces Positive Phase II Results for,PRT054021 for Prevention of Venous Thromboembolism Following Total,Knee Replacement Surgery 3
With this unique offer, you can prepare for any molecular biology application. Pipetman P2 and P10 are ideal for enzymes and reagents, and P100 is perfect for buffers. Kits include Diamond Filter Tip
The RapidPCP test is an immunochromatography based one step in vitro test. It is,designed for qualitative determination of Phencyclidine in human urine specimens above,a cut-off level of 25 ng/mL. Th
... an immunochromatography based one step,in vitro t...of Opiates and its metabolite in,human urine speci...e a cut-off level,of 2,000ng/mL can be detected. T...are,location and is for use by Healthcare Professi...
All of DOA Panel Test is an immunochromatography based one step in vitro test. It is designed,for qualitative determination of drug substances in human urine specimens. This assay has not,been evalua
Medicine Products: